Signature Estate & Investment Advisors LLC Buys 11,010 Shares of Pfizer Inc. (NYSE:PFE)

Signature Estate & Investment Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 106.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 21,394 shares of the biopharmaceutical company’s stock after acquiring an additional 11,010 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Pfizer were worth $599,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. GUNN & Co INVESTMENT MANAGEMENT INC. bought a new position in Pfizer during the fourth quarter worth about $2,601,000. Intellectus Partners LLC lifted its position in shares of Pfizer by 11.1% during the fourth quarter. Intellectus Partners LLC now owns 83,435 shares of the biopharmaceutical company’s stock worth $2,402,000 after acquiring an additional 8,352 shares in the last quarter. Silver Oak Securities Incorporated boosted its holdings in shares of Pfizer by 51.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 13,368 shares of the biopharmaceutical company’s stock worth $385,000 after acquiring an additional 4,522 shares during the period. Eagle Wealth Strategies LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $208,000. Finally, Gilbert & Cook Inc. raised its stake in shares of Pfizer by 3.8% during the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 945 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, August 19th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Performance

Shares of PFE stock opened at $28.84 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $36.94. The company has a market capitalization of $163.40 billion, a P/E ratio of -480.58, a PEG ratio of 0.98 and a beta of 0.69. The stock has a 50 day moving average price of $28.89 and a two-hundred day moving average price of $27.98.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the prior year, the company posted $0.67 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.83%. Pfizer’s dividend payout ratio is currently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.